| 引用本文:毛宇湘1，张志威1，钱金花1，管佳畅2，孟宗德2.软坚开肺利水法治疗肝硬化腹水的临床研究[J].世界中医药,2016,(11):. |
|
| 软坚开肺利水法治疗肝硬化腹水的临床研究 |
| Comprehensive Program of Research on Cirrhosis with Massive Ascites treated with Softening hardness kaifei lishui Therapy |
| 投稿时间：2016-01-21 |
| DOI：10.3969/j.issn.1673-7202.2016.11.010 |
| 中文关键词: 肝硬化腹水 软坚开肺利水 临床研究 |
| English Keywords:Cirrhosis with ascites Softening hardness,kaifei lishui Clinical observation |
| 基金项目:河北省中医药管理局科研课题(编号:2012023) |
|
| 摘要点击次数: 687 |
| 全文下载次数: 739 |
| 中文摘要: |
| 目的:观察具有软坚开肺利水功效的复肝春3号方对肝硬化腹水患者的临床疗效。方法:将符合肝硬化腹水诊断要求的患者120例,随机分为治疗组及对照组,每组60例。治疗组在西医常规治疗的基础上加用复肝春3号方治疗;对照组应用西医常规治疗。20 d为1个疗程,观察患者的中医症状、体征,肝功能,腹部彩超等指标。结果:2组治疗前、后症状、体征积分相比(P<005),两者之间差异有统计学意义,治疗组优于对照组;肝功能指标:2组治疗前后ALB、ALT、AST、TBIL均有所改善,其余指标无显著性差异,2组患者腹部超声比较:门静脉内径,脾厚治疗前、后数据无统计学意义,疗效差异无统计学意义;但在腹水减退方面治疗前、后差异有统计学意义,治疗组优于对照组。结论:复肝春3号方能有效消退患者腹水,改善患者的临床症状,改善肝功能,提高患者的生活质量。尤其在联合西医对症治疗方面,具有明显的临床优势,值得临床推广运用。 |
| English Summary: |
| Observed using Softening hardness kaifei Lishui therapy composed with promoting blood circulation Softening hardness clinical efficacy open lung lishui efficacy Fu gan chun the 3rd Prescription(FGC-3)cirrhosis with ascites patients the clinical treatment.Methods:Inpatient will meet the requirements of 120 cases of liver cirrhosis diagnosis，divided into treatment group and the control group.Treatment of a group of 60 patients with(FGC-3)combined conventional medicine symptomatic treatment； the control group of 60 patients with medicine symptomatic treatment.20 days for treatment.Observe these three groups of patients before treatment，clinical symptoms in patients with traditional Chinese medicine，signs，liver function，B-ultrasound and other test indicators，and according to Response Evaluation Criteria，making clinical evaluation.Results:Two groups after treatment symptom score compared,(P<005)，there was a significant difference between them.the treatment group than the control group；Hepatic function：two groups before and after treatment ALB，ALT，AST，TBIL have improved；two groups of patients with abdominal B ultrasound(portal vein width，thickness of spleen，ascites depth)the data was not statistically significant，they were no significant difference in efficacy； But before treatment in ascites diminished respect after a significant difference.Conclusion:The results of this study showed that the benefits of(FGC-3)effective in patients with ascites subsided，improve clinical symptoms，improve liver function and improve the quality of life of patients.It is very useful Especially in the symptomatic treatment of medicine combined with significant clinical advantages. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|
